Vasodilator therapy of dilated cardiomyopathy
Open Access
- 1 June 1986
- journal article
- research article
- Published by Oxford University Press (OUP)
- Vol. 62 (728) , 599-600
- https://doi.org/10.1136/pgmj.62.728.599
Abstract
Summary: Vasoconstriction increases impedance to ventricular ejection and impairs the performance of the dilated myopathic heart. Vasodilator drug therapy by reducing vascular resistance, increasing vascular compliance and increasing vascular capacitance improves cardiac function and relieves the signs and symptoms of congestive heart failure. Earlier intervention in an attempt to alter the natural history of cardiomyopathy should be studied.Keywords
This publication has 9 references indexed in Scilit:
- Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart FailureNew England Journal of Medicine, 1984
- A placebo-controlled trial of captopril in refractory chronic congestive heart failureJournal of the American College of Cardiology, 1983
- Regional blood flow response to orthostasis in patients with congestive heart failureJournal of the American College of Cardiology, 1983
- Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failureThe American Journal of Cardiology, 1982
- Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure.Circulation, 1980
- Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure.Circulation, 1978
- Treatment of Refractory Heart Failure with Infusion of NitroprussideNew England Journal of Medicine, 1974
- Beneficial Effects of Vasodilator Agents in Severe Mitral Regurgitation Due to Dysfunction of Subvalvar ApparatusCirculation, 1973
- Vasodilator Therapy for Heart FailureCirculation, 1973